In May 2026, COMPASS Pathways plc elected Kathleen Tregoning to its Board of Directors, with plans for her to join the Compensation and Leadership Development Committee and the Nominating and ...
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...
Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Recent attention on COMPASS Pathways (CMPS) centers on its first quarter 2026 ...
MarketBeat on MSN
Compass Pathways eyes Q4 FDA filing for psilocybin depression drug after phase 3 wins
Key Points Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better. Compass Pathways said it ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the exercise of ...
心理健康医疗公司Compass Pathways Plc(CMPS)股价触及52周高点$11.65,创下重要里程碑。该股目前交易价格为$11.68,市值达15.7亿美元。过去一年间,Compass Pathways股价累计涨幅高达150%,充分反映出投资者对其创新心理健康疗法的信心持续增强。此番股价攀升至52周高位 ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial ...
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...
Artificial Intelligence (AI) is rapidly penetrating a number of different sectors, including healthcare. The use of AI in mental health has opened up the possibility of new avenues of care, ...
Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果